gdc
FDA Approvals, News & UpdatesLeukemiaNewsworthy

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

December 2017 Vol 3 No 6

On August 17, 2017, the FDA approved the targeted therapy Besponsa (inotuzumab ozogamicin; from Pfizer) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

This approval was based on a clinical trial that showed complete response to therapy with Besponsa in more than one-third of patients who received the drug. Serious side effects include liver toxicity, such as veno-occlusive disease or sinusoidal obstruction syndrome, as well as increased risk of death if used after certain stem-cell transplants.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLeukemiaLymphoma
FDA Approved Rylaze as Part of a Treatment Regimen for Young Patients with Leukemia or Lymphoma
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection.
FDA Approvals, News & UpdatesMultiple Myeloma
Darzalex Faspro Receives New FDA Indication, in Combination with Pomalyst and Dexamethasone, for the Treatment of Patients with Multiple Myeloma
In July 2021, the FDA approved a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj), for use in combination with Pomalyst (pomalidomide) and dexamethasone, for adults with multiple myeloma who have received at least 1 previous line of therapy.
CholangiocarcinomaFDA Approvals, News & Updates
Truseltiq Second Targeted Therapy Approved by the FDA for Patients with Advanced or Metastatic Cholangiocarcinoma and the FGFR2 Biomarker
In late May 2021, the FDA approved Truseltiq (infigratinib), a new targeted therapy, for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusion or other rearrangement, as detected by an FDA-approved test.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest